John Oyler, BeiGene CEO (Endpoints News, PharmCube)

BeiGene ex­pands pipeline and hops on board a quest to cure hep B, ink­ing a $540M deal with a fel­low up­start biotech

Chi­na biotech BeiGene $BGNE is step­ping up with $40 mil­lion in cash and $500 mil­lion for a smor­gas­bord of mile­stones to part­ner with up­start As­sem­bly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.